Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling
Jingyue Yao(China Pharmaceutical University), Libin Wei(China Pharmaceutical University)
Cited by 51
Related Papers
Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism
|Cell Death and Disease|2017|87
RETRACTED ARTICLE: Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression
|Cell Death and Disease|2017|70
Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells
|Journal of Hematology & Oncology|2015|67
Lactate promotes PGE2 synthesis and gluconeogenesis in monocytes to benefit the growth of inflammation-associated colorectal tumor
|Oncotarget|2015|41
Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells
|The International Journal of Biochemistry & Cell Biology|2013|41